Proton Pump Inhibitors. Investigating Their Role in Small Intestinal Bacterial Overgrowth

Proton pump inhibitors (PPIs) are widely used medications known for their effectiveness in reducing gastric acid production and their overall safety profile. Despite being valued for these properties, concerns have been raised regarding potential adverse effects associated with their long-term use....

Full description

Saved in:
Bibliographic Details
Published in:Quality in Sport 2024-08, Vol.20, p.54123
Main Authors: Kruszewski, Adrian, Szyszka, Monika, Kucharska, Maja, Przybysz, Paulina, Kwiliński, Kacper, Wawrzyńska, Barbara, Rydlakowska-Orozco, Natalia
Format: Article
Language:English
Subjects:
PPI
proton pump inhibitors
SIBO
small intestinal bacterial overgrowth
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proton pump inhibitors (PPIs) are widely used medications known for their effectiveness in reducing gastric acid production and their overall safety profile. Despite being valued for these properties, concerns have been raised regarding potential adverse effects associated with their long-term use. Various studies indicate a higher prevalence of small intestinal bacterial overgrowth (SIBO) in patients on prolonged PPI therapy, with symptoms ranging from bloating and diarrhea to malabsorption and nutrient deficiencies. Diagnosing SIBO primarily involves non-invasive breath tests that measure hydrogen and methane levels produced by bacterial fermentation after ingesting a carbohydrate substrate, such as lactulose or glucose. Direct aspiration and culture of small intestinal fluid offer a more definitive diagnosis but are invasive and less commonly performed. Treatment of SIBO focuses on reducing bacterial overgrowth by using antibiotics.This review aims to inform clinicians about the possible risks of PPI therapy and the importance of suspecting SIBO in patients with nonspecific gastrointestinal symptoms.
ISSN:2450-3118
2450-3118
DOI:10.12775/QS.2024.20.54123